Pfizer: signs license deal for Theravance's skin program
(CercleFinance.com) - Pfizer said it has entered into a license agreement with Theravance for a drug development project covering patients with mild-to-moderate skin conditions, for whom treatment is currently limited.
The deal includes Theravance's preclinical program for locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
The compounds in this program target validated pro-inflammatory pathways and are specifically designed to have skin-selective activity and minimal systemic exposure.
Under the terms of the deal, Theravance will receive an upfront cash payment of 10 million dollars and will be eligible to receive up to an additional 240 million dollars in development and sales milestone payments from Pfizer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The deal includes Theravance's preclinical program for locally-acting pan-Janus kinase (JAK) inhibitors that can be rapidly metabolized.
The compounds in this program target validated pro-inflammatory pathways and are specifically designed to have skin-selective activity and minimal systemic exposure.
Under the terms of the deal, Theravance will receive an upfront cash payment of 10 million dollars and will be eligible to receive up to an additional 240 million dollars in development and sales milestone payments from Pfizer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.